Alnylam Pharmaceuticals (ALNY) news
Recent news
Alnylam shares down 4.9% premarket after rival trial data
Alnylam Pharmaceuticals (ALNY) shares fell 4.9% in premarket trading following the release of data from a rival trial, marking a reversal from recent gains driven by setbacks in competing therapies for ATTR cardiomyopathy. Despite the recent rally, Alnylam’s stock has declined 25.34% year to date,…
AInvest Wire · 3d agoAlnylam Pharmaceuticals (ALNY) fell 5.39% in intraday trading after rising 6.12% on Wednesday, marking a reversal of the prior session's move
AInvest Wire · Aug 20, 2026Alnylam Pharmaceuticals (ALNY) shares rose 6.24% in intraday trading after BMO Capital Markets initiated coverage with an Outperform rating and a $318 price target.
Alnylam Pharmaceuticals (NASDAQ:ALNY) shares rose 6.24% in intraday trading after BMO Capital Markets initiated coverage with an Outperform rating and a $318 price target . The stock has faced downward pressure in recent months, declining 42.5% year-to-date and trading at $228.61, or 54% below its…
AInvest Wire · Aug 19, 2026Alnylam Pharmaceuticals Inc: Truist Securities cuts target price to $315 from $410
Truist Securities has lowered its price target for Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) to $315 from $410, reflecting a more cautious outlook amid recent financial developments. This adjustment follows Alnylam’s second-quarter 2026 results, which showed a 74% year-over-year increase in net…
AInvest Wire · Aug 3, 2026Alnylam Pharmaceuticals Inc: Bernstein cuts target price to $376 from $429
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.